To	O
address	O
this	O
secondary	O
aim	O
,	O
the	O
main	O
parameters	O
are	O
observational	O
and	O
questionnaire	O
measures	B-O
of	I-O
parental	I-O
availability	I-O
,	I-O
parent-child	I-O
relationship	I-O
variables	I-O
,	I-O
children	I-O
's	I-O
adjustment	I-O
problems	I-O
and	I-O
children	I-O
's	I-O
responses	I-O
to	O
interparental	O
violence	O
.	O


BACKGROUND	O
The	O
aim	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
characteristics	O
of	O
acute	O
myocardial	O
infarction	O
in	O
patients	B-P
undergoing	I-P
surgery	I-P
for	I-P
acute	I-P
hip	I-P
fracture	I-P
.	I-P


Troponin	B-I
T	I-I
(	I-I
TnT	I-I
)	I-I
measurements	I-I
and	O
electrocardiographic	B-I
(	I-I
ECG	I-I
)	I-I
recordings	I-I
were	O
performed	O
at	O
admission	O
,	O
before	O
operation	O
,	O
and	O
on	O
the	O
first	O
and	O
2nd	O
postoperative	O
days	O
,	O
which	O
were	O
used	O
for	O
diagnosis	O
.	O


How	O
to	O
establish	O
equivalence	O
when	O
data	O
are	O
censored	O
:	O
a	O
randomized	B-P
trial	I-P
of	I-P
treatments	I-P
for	I-P
B	I-P
non-Hodgkin	I-P
lymphoma	I-P
.	I-P


In	O
cancer	O
research	O
we	O
are	O
more	O
often	O
concerned	O
with	O
survival	B-O
.	I-O


An	O
equivalence	O
trial	O
of	O
maintenance	B-I
therapy	I-I
was	O
carried	O
out	O
in	O
children	B-P
with	I-P
B	I-P
non-Hodgkin	I-P
lymphoma	I-P
,	O
and	O
serves	O
as	O
an	O
illustration	O
.	O


There	O
were	O
four	B-I
randomised	I-I
treatment	I-I
phases	I-I
,	O
each	O
of	O
4	O
weeks	O
duration	O
.	O


Clinic	B-O
BP	I-O
was	O
measured	O
weekly	O
with	O
the	O
mean	O
values	O
of	O
weeks	O
3	O
and	O
4	O
of	O
each	O
phase	O
used	O
for	O
analysis	O
.	O


RESULTS	O
Compared	O
with	O
the	O
placebo	O
phase	O
,	O
end	O
of	O
phase	O
clinic	B-O
BP	I-O
was	O
unchanged	O
by	O
any	O
of	O
the	O
progestogen	O
treatments	O
.	O


RESULTS	O
At	O
end	O
point	O
,	O
reductions	B-O
in	I-O
ADHD	I-O
,	I-O
depressive	I-O
,	I-O
and	I-O
anxiety	I-O
symptoms	I-O
were	O
marked	O
for	O
both	O
treatment	O
groups	O
(	O
p	O
<	O
.001	O
for	O
the	O
relevant	O
scale	O
in	O
each	O
symptom	O
cluster	O
)	O
.	O


Some	O
differences	B-O
between	O
treatment	O
groups	O
for	O
depressive	B-O
symptoms	I-O
were	O
significant	B-O
,	O
but	O
the	O
magnitudes	B-O
of	O
the	O
differences	O
were	O
small	B-O
and	O
likely	O
of	O
limited	O
clinical	O
importance	O
.	O


A	O
coronary	B-I
arteriography	I-I
was	O
done	O
on	O
study	O
entry	O
.	O


Individual	O
groups	O
analysis	O
showed	O
significative	O
reductions	B-O
of	O
SAP	B-O
,	I-O
DAP	I-O
and	I-O
HR	I-O
in	O
propranolol	B-I
group	O
.	O


The	O
two	B-P
treatment	I-P
groups	I-P
were	I-P
closely	I-P
matched	I-P
in	I-P
age	I-P
,	I-P
sex	I-P
,	I-P
per	I-P
cent	I-P
of	I-P
BSA	I-P
burned	I-P
,	I-P
and	I-P
in	I-P
burn	I-P
severity	I-P
and	I-P
locations	I-P
.	I-P


The	O
MVPF	B-I
group	O
demonstrated	O
a	O
39.0	O
per	O
cent	O
greater	O
reduction	O
in	O
pain	B-O
after	O
application	O
of	O
the	O
dressing	O
over	O
the	O
silver	B-I
sulphadiazine	I-I
group	O
.	O


The	O
clinical	B-O
infection	I-O
rate	I-O
and	I-O
time	I-O
to	I-O
healing	I-O
were	O
similar	O
in	O
both	O
groups	O
.	O


In	O
discrimination	O
learning	O
paradigm	O
,	O
children	O
receiving	O
haloperidol	B-I
learned	I-O
the	I-O
discrimination	I-O
while	O
those	O
on	O
placebo	B-I
did	O
not	O
.	O


Discrimination	O
attained	O
on	O
haloperidol	B-I
was	O
retained	O
when	O
the	O
children	O
were	O
switched	O
to	O
placebo	B-I
.	I-I


METHODS	O
A	O
series	O
of	O
134	B-P
patients	I-P
were	I-P
included	I-P
at	I-P
7	I-P
hospital	I-P
centers	I-P
.	I-P


Patients	O
completed	O
a	O
questionnaire	B-I
before	O
and	O
1	O
year	O
after	O
surgery	O
to	O
evaluate	O
symptoms	O
,	O
function	O
,	O
and	O
overall	O
satisfaction	O
.	O


A	O
clear	O
difference	O
in	O
morphine	B-O
requirement	I-O
became	O
evident	O
after	O
24	O
hours	O
(	O
P	O
=	O
0.010	O
)	O
.	O


At	O
1	O
year	O
,	O
no	O
differences	B-O
in	O
the	O
resolution	B-O
of	I-O
symptoms	I-O
were	O
observed	O
between	O
the	O
2	O
groups	O
,	O
and	O
over	O
2	O
years	O
,	O
the	O
overall	B-O
incidence	I-O
of	I-O
complications	I-O
was	O
the	O
same	O
,	O
specifically	O
fecaloma	B-O
(	O
P	O
=	O
0.003	O
)	O
in	O
the	O
MM	B-I
group	O
and	O
external	B-O
hemorrhoidal	I-O
thrombosis	I-O
(	O
P	O
=	O
0.006	O
)	O
in	O
the	O
SH	B-I
group	O
.	O


No	O
patient	O
needed	O
a	O
second	B-O
procedure	I-O
for	O
recurrence	O
within	O
2	O
years	O
,	O
although	O
partial	B-O
residual	I-O
prolapse	I-O
was	O
detected	O
in	O
4	O
SH	B-I
patients	O
(	O
7.5	O
%	O
)	O
versus	O
1	O
MM	B-I
patient	O
(	O
1.8	O
%	O
)	O
(	O
P	O
=	O
0.194	O
)	O
.	O


CONCLUSION	O
Stapled	B-I
hemorrhoidopexy	I-I
causes	O
significantly	O
less	O
postoperative	B-O
pain	I-O
.	I-O


Like	O
with	O
conventional	O
surgery	B-I
,	O
anorectal	B-O
dysfunction	I-O
can	O
occur	O
after	O
stapled	B-I
hemorrhoidopexy	I-I
in	O
some	O
patients	O
.	O


Hemorroidopexy	B-I
is	O
applicable	O
for	O
treating	O
reducible	O
hemorrhoidal	O
prolapse	O
.	O


In	O
this	O
study	O
we	O
examined	O
the	O
social	O
behaviors	O
of	O
4-	B-P
to	I-P
12-year-old	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
;	I-P
N	I-P
=	I-P
24	I-P
)	I-P
during	O
three	O
tradic	O
interactions	O
with	O
an	B-I
adult	I-I
confederate	I-I
and	I-I
an	I-I
interaction	I-I
partner	I-I
,	O
where	O
the	O
interaction	O
partner	O
varied	O
randomly	O
among	O
(	B-I
1	I-I
)	I-I
another	I-I
adult	I-I
human	I-I
,	I-I
(	I-I
2	I-I
)	I-I
a	I-I
touchscreen	I-I
computer	I-I
game	I-I
,	I-I
and	I-I
(	I-I
3	I-I
)	I-I
a	I-I
social	I-I
dinosaur	I-I
robot	I-I
.	O


Tumor	B-O
budding	I-O
is	O
an	O
independent	O
predictor	O
of	O
outcome	O
in	O
AJCC/UICC	B-P
stage	I-P
II	I-P
colorectal	I-P
cancer	I-P
.	I-P


For	O
multivariable	B-I
analysis	I-I
,	O
Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
were	O
performed	O
.	O


OBJECTIVES	O
To	O
verify	O
non-inferiority	O
of	O
the	O
clinical	O
pregnancy	O
rate	O
of	O
Early	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
16.0-16.9	O
mm	O
in	O
diameter	O
)	O
compared	O
to	O
Late	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
18.0-18.9	O
mm	O
in	O
diameter	O
)	O
.	O


CONCLUSION	O
These	O
results	O
suggest	O
that	B-I
hCG	I-I
administered	O
when	O
the	O
largest	O
follicle	O
size	O
reaches	O
16.0-16.9	O
mm	O
leads	O
to	O
similar	O
clinical	O
and	O
ongoing	O
pregnancy	O
rates	O
as	O
when	O
it	O
reaches	O
18.0-18.9	O
mm	O
in	O
IUI	O
cycles	O
.	O


Managing	O
repetitive	O
behaviours	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
:	I-P
pilot	O
randomised	O
controlled	O
trial	O
of	O
a	O
new	O
parent	B-P
group	O
intervention	O
.	O


In	O
response	O
to	O
improved	O
blood	O
folate	O
concentrations	O
,	O
many	O
health	O
care	O
professionals	O
are	O
asking	O
whether	O
a	O
folic	B-I
acid	I-I
supplement	I-I
is	O
necessary	O
for	O
NTD	O
prevention	O
among	O
women	B-P
with	I-P
high	I-P
blood	I-P
folate	I-P
values	I-P
,	O
and	O
how	O
reliably	O
high	O
RBC	O
folate	O
concentrations	O
predict	O
folate	O
intakes	O
shown	O
in	O
randomized	O
controlled	O
trials	O
to	O
be	O
protective	O
against	O
NTDs	O
.	O


Only	O
modest	O
associations	O
existed	O
between	O
total	B-O
folate	I-O
intakes	I-O
and	O
plasma	B-O
(	O
r	O
=	O
0.46	O
,	O
P	O
<	O
0.001	O
)	O
and	O
RBC	O
(	O
r	O
=	O
0.36	O
,	O
P	O
<	O
0.01	O
)	O
folate	B-O
concentrations	I-O
at	O
16-wk	O
postpartum	O
.	O


Plasma	B-O
and	I-O
RBC	I-O
folate	I-O
values	I-O
at	O
16-wk	O
postpartum	O
correctly	O
identified	O
the	O
quartile	O
of	O
folate	O
intake	O
of	O
only	O
26	O
of	O
55	O
(	O
47	O
%	O
)	O
and	O
18	O
of	O
55	O
(	O
33	O
%	O
)	O
of	O
subjects	O
,	O
respectively	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
treatment	O
outcomes	B-O
after	O
guided	B-I
tissue	I-I
regeneration	I-I
(	I-I
GTR	I-I
)	I-I
with	O
a	O
bioabsorbable	O
membrane	O
in	O
Class	B-P
II	I-P
furcation	I-P
defects	I-P
in	O
mandibular	O
molars	O
.	O


METHODS	O
Nine	B-P
patients	I-P
,	I-P
with	I-P
two	I-P
comparable	I-P
Class	I-P
II	I-P
furcation	I-P
defects	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


The	O
radiographs	B-I
were	O
analyzed	O
by	O
subtraction	O
radiography	O
.	O


GTR	B-I
provided	O
complete	O
closure	B-O
of	I-O
the	I-O
furcation	I-O
defect	I-O
in	O
two	O
sites	O
and	O
superior	B-O
horizontal	I-O
clinical	I-O
attachment	I-O
level	I-O
gain	I-O
(	O
GTR	O
:	O
2.27	O
mm	O
;	O
OFD	O
:	O
1.01	O
mm	O
,	O
P	O
=	O
0.05	O
)	O
.	O


No	O
overall	O
trend	O
for	O
lower	O
RU	B-O
was	O
associated	O
with	O
sibenadet	O
therapy	O
,	O
which	O
correlates	O
with	O
the	O
lack	O
of	O
sustained	O
clinical	O
effect	O
seen	O
in	O
studies	O
conducted	O
concurrently	O
.	O


Using	O
the	O
belief	B-I
basis	I-I
of	I-I
the	I-I
theory	I-I
of	I-I
planned	I-I
behavior	I-I
(	I-I
TPB	I-I
)	I-I
,	O
the	O
current	O
study	O
explored	O
the	O
rate	B-O
of	I-O
mild	I-O
reactions	I-O
reported	O
by	O
donors	O
in	O
relation	O
to	O
their	O
first	O
donation	O
and	O
the	O
intention	O
and	O
beliefs	O
of	O
those	O
donors	O
with	O
regard	O
to	O
returning	O
to	O
donate	O
again	O
.	O


The	O
vascular	B-P
femoral	I-P
head	I-P
necrosis	I-P
is	I-P
a	I-P
serious	I-P
illness	I-P
,	I-P
especially	I-P
when	I-P
appearing	I-P
in	I-P
patients	I-P
aged	I-P
30	I-P
to	I-P
50	I-P
years	I-P
.	I-P


The	O
evaluation	O
of	O
the	O
signal	O
intensity	O
by	O
the	O
dynamic	B-O
screening	I-O
sequence	I-O
is	O
considered	O
as	O
an	O
objective	O
contribution	O
for	O
the	O
staging	B-O
of	I-O
the	I-O
femoral	I-O
head	I-O
necrosis	I-O
.	I-O


This	O
enables	O
one	O
to	O
differentiate	O
between	B-P
the	I-P
curable	I-O
stage	I-O
IIc	I-O
and	I-P
the	I-P
stage	I-O
III	I-O
,	I-P
showing	I-P
the	I-P
beginning	I-P
of	I-P
breakdown	I-O
of	I-O
the	I-O
femoral	I-O
head	I-O
.	I-O


Aminocaproic	B-I
acid	I-I
versus	O
prednisone	B-I
for	O
the	O
treatment	O
of	O
traumatic	B-P
hyphema	I-P
.	I-P


Blacks	B-P
comprised	I-P
53	I-P
%	I-P
of	I-P
the	I-P
study	I-P
population	I-P
,	I-P
and	I-P
the	I-P
mean	I-P
age	I-P
of	I-P
the	I-P
patients	I-P
was	I-P
23.5	I-P
years	I-P
.	I-P


Sun	B-I
protection	I-I
behaviors	I-I
and	O
stages	O
of	O
change	O
for	O
the	O
primary	O
prevention	O
of	O
skin	B-P
cancers	I-P
among	I-P
beachgoers	I-P
in	I-P
southeastern	I-P
New	I-P
England	I-P
.	I-P


We	O
report	O
characteristics	O
of	O
a	O
representative	B-P
sample	I-P
(	I-P
N	I-P
=	I-P
2,324	I-P
)	I-P
of	I-P
beachgoers	I-P
in	I-P
Southeastern	I-P
New	I-P
England	I-P
during	I-P
the	I-P
summer	I-P
of	I-P
1995	I-P
.	I-P


Hyperbaric	B-I
oxygen	I-I
attenuation	O
of	O
lipopolysaccharide-induced	B-P
acute	I-P
lung	I-P
injury	I-P
involves	O
heme	O
oxygenase-1	O
.	O


With	O
or	O
without	O
HBO	B-I
pre-treatment	O
,	O
the	O
rats	B-P
were	O
further	O
divided	O
into	O
the	O
following	O
subgroups	O
(	O
n	O
=	O
6	O
)	O
:	O
(	O
i	O
)	O
LPS	B-I
injection	I-I
,	I-I
(	I-I
ii	I-I
)	I-I
normal	I-I
saline	I-I
(	I-I
N/S	I-I
)	I-I
injection	I-I
,	I-I
(	I-I
iii	I-I
)	I-I
hemin	I-I
(	I-I
a	I-I
HO-1	I-I
inducer	I-I
)	I-I
plus	I-I
LPS	I-I
,	I-I
(	I-I
iv	I-I
)	I-I
hemin	I-I
alone	I-I
,	I-I
(	I-I
v	I-I
)	I-I
tin	I-I
protoporphyrin	I-I
(	I-I
SnPP	I-I
;	I-I
a	I-I
HO-1	I-I
inhibitor	I-I
)	I-I
plus	I-I
LPS	I-I
,	I-I
and	I-I
(	I-I
vi	I-I
)	I-I
SnPP	I-I
alone	I-I
.	I-I


CONCLUSIONS	O
HBO	B-I
may	O
act	O
through	O
inhibiting	O
pulmonary	O
iNOS	O
expression	O
to	O
attenuate	O
LPS-induced	O
acute	O
lung	O
injury	O
in	O
septic	B-P
rats	I-P
.	I-P


OBJECTIVE	O
One-third	O
of	O
the	O
total	O
population	O
seems	O
to	O
develop	O
minor	O
recurrent	B-P
aphthous	I-P
stomatitis	I-P
(	I-P
RAS	I-P
)	I-P
during	O
their	O
lifetime	O
.	O


The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
prevalence	O
of	O
RAS	O
decreased	O
with	O
perilla	B-I
oil	I-I
(	O
rich	O
in	O
alpha-linolenic	O
acid	O
)	O
.	O


Blood	B-O
samples	I-O
were	O
collected	O
at	O
the	O
start	O
and	O
end	O
of	O
the	O
experimental	O
phase	O
for	O
fatty	O
acid	O
analysis	O
of	O
total	O
plasma	O
phospholipid	O
fraction	O
.	O


Occurrence	B-O
and	I-O
needed	I-O
days	I-O
for	I-O
healing	I-O
of	I-O
minor	I-O
RAS	I-O
were	O
recorded	O
during	O
the	O
two	O
phases	O
and	O
compared	O
.	O


RESULTS	O
alpha-Linolenic	B-O
acid	I-O
concentrations	I-O
in	I-O
the	I-O
plasma	I-O
phospholipid	I-O
fraction	I-O
increased	I-O
significantly	O
in	O
both	O
groups	O
during	O
the	O
experimental	O
phase	O
to	O
a	O
similar	O
extent	O
.	O


The	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-P
turnover	I-P
in	I-P
postmenopausal	I-P
women	I-P
.	I-P


The	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
therapy	O
on	O
bone	O
turnover	O
is	O
unknown	O
.	O


Our	O
aim	O
was	O
to	O
determine	O
the	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-O
turnover	I-O
and	O
bone	B-O
mineral	I-O
density	I-O
(	I-O
BMD	I-O
)	I-O
in	O
postmenopausal	B-P
,	I-P
osteopenic	I-P
women	I-P
.	I-P


Women	B-P
aged	I-P
50	I-P
to	I-P
80	I-P
years	I-P
received	O
raloxifene	B-I
for	O
96	O
weeks	O
and	O
were	O
then	O
randomized	O
to	O
continue	O
raloxifene	B-I
(	I-P
group	I-P
1	I-P
,	I-P
n=20	I-P
)	I-P
or	I-I
placebo	I-I
(	I-P
group	I-P
2	I-P
,	I-P
n=20	I-P
)	I-P
for	I-P
a	I-P
further	I-P
96	I-P
weeks	I-P
.	I-P


Continuation	O
of	O
raloxifene	B-I
(	O
group	O
1	O
)	O
maintained	O
these	O
changes	O
.	O


Following	O
cessation	O
of	O
raloxifene	B-I
(	O
group	O
2	O
)	O
,	O
bone	B-O
markers	I-O
returned	O
to	O
baseline	O
levels	O
(	O
by	O
120	O
weeks	O
)	O
.	O


Hip	B-O
BMD	I-O
was	O
decreased	O
by	O
2	O
%	O
at	O
192	O
weeks	O
compared	O
to	O
baseline	O
.	O


Bone	B-O
loss	I-O
following	O
cessation	O
of	O
raloxifene	B-I
therapy	O
at	O
96	O
weeks	O
was	O
greater	O
than	O
in	O
the	O
control	O
group	O
,	O
suggesting	O
accelerated	B-P
bone	I-P
loss	I-P
.	I-P


The	O
beneficial	O
effect	O
on	O
bone	B-O
turnover	I-O
of	O
96	O
weeks	O
of	O
raloxifene	O
was	O
lost	O
6	O
months	O
after	O
cessation	O
of	O
treatment	O
.	O


Effects	O
of	O
hydraulic	O
circuit	O
training	O
on	O
cardiovascular	B-P
function	I-P
.	I-P


Maximal	B-O
aerobic	I-O
power	I-O
(	I-O
VO2max	I-O
)	I-O
,	I-O
with	I-O
simultaneous	I-O
measurement	I-O
of	I-O
stroke	I-O
volume	I-O
(	I-O
SV	I-O
)	I-O
and	I-O
cardiac	I-O
output	I-O
(	I-O
CO	I-O
)	I-O
,	I-O
by	I-O
impedance	I-O
cardiography	I-O
,	O
was	O
assessed	O
pre-	O
and	O
post-training	O
.	O


Following	O
training	O
VO2max	B-O
(	I-O
ml.kg-1	I-O
min-1	I-O
)	I-O
was	O
significantly	O
increased	O
in	O
all	O
training	O
groups	O
(	O
18.0	O
,	O
12.5	O
,	O
and	O
11.3	O
%	O
for	O
cycle	O
,	O
HCTsub	O
,	O
and	O
HCTmax	B-O
groups	I-O
,	O
respectively	O
;	O
P	O
less	O
than	O
0.05	O
)	O
.	O


HR	B-O
changes	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
were	O
significantly	O
less	O
in	O
KC30	O
and	O
KC15	O
than	O
in	O
IC	O
,	O
and	O
more	O
infants	O
had	O
HR	B-O
decrease	O
in	O
IC	O
than	O
in	O
2	O
KC	O
conditions	O
.	O


In	O
all	O
3	O
conditions	O
,	O
LF/HF	B-O
ratio	I-O
decreased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
increased	O
to	O
Recovery	O
;	O
no	O
differences	O
were	O
found	O
between	O
IC	B-I
and	O
two	O
KC	B-I
conditions	O
.	O


Both	O
longer	O
and	O
shorter	O
KC	B-I
before	O
and	O
throughout	O
heel	O
stick	O
can	O
stabilize	O
HR	B-O
response	I-O
in	O
preterm	O
infants	O
,	O
and	O
longer	O
KC	B-I
significantly	O
affected	O
infants	O
'	O
sympathetic	O
and	O
parasympathetic	O
responses	O
during	O
heel	O
stick	O
compared	O
with	O
incubator	B-I
care	I-I
.	I-I


In	B-P
2003	I-P
50	I-P
patients	I-P
treated	I-P
with	I-P
one	I-I
or	I-I
two	I-I
epidural	I-I
injections	I-I
have	I-P
been	I-P
selected	I-P
"	I-P
ad	I-P
random	I-P
"	I-P
and	I-P
50	I-P
patients	I-P
treated	I-P
with	I-P
disc	I-I
coablation	I-I
.	I-I


Finally	O
,	O
average	B-O
VAS	I-O
was	O
clearly	O
lower	O
(	O
p	O
<	O
0.01	O
)	O
after	O
coablation	O
as	O
compared	O
to	O
epidural	B-I
injections	I-I
.	O


51	B-P
patients	I-P
were	O
divided	O
into	O
two	O
groups	O
:	O
one	O
in	O
acupuncture	B-I
treatment	I-I
and	O
the	O
other	O
without	O
any	O
treatment	O
.	O


This	O
result	O
revealed	O
that	O
acupuncture	B-I
seemed	O
to	O
have	O
more	O
affect	O
on	O
OKT4+	B-O
cells	I-O
than	O
on	O
OKT8+	B-O
cells	I-O
.	I-O


RESULTS	O
PECS	B-O
was	I-O
more	I-O
successful	I-O
than	I-O
RPMT	I-O
in	I-O
increasing	I-O
the	I-O
number	I-O
of	I-O
nonimitative	I-O
spoken	I-O
communication	I-O
acts	I-O
and	I-O
the	I-O
number	I-O
of	I-O
different	I-O
nonimitative	I-O
words	I-O
used	I-O
at	I-O
the	I-O
posttreatment	I-O
period	I-O
.	I-O


In	O
contrast	O
,	O
analogous	B-O
slopes	I-O
were	O
steeper	O
in	O
the	O
RPMT	O
group	O
than	O
in	O
the	O
PECS	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
low	O
object	O
exploration	O
.	O


All	O
cavities	B-P
received	O
the	O
same	O
adhesive	O
system	O
and	O
were	O
restored	O
with	O
flowable	O
composite	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O


CONCLUSIONS	O
It	O
can	O
be	O
concluded	O
that	O
no	O
significant	O
difference	O
was	O
noted	O
between	O
the	O
two	O
types	O
of	O
enamel	B-I
preparation	I-I
when	O
etching	O
was	O
performed	O
.	O


Preparing	O
and	O
treating	O
the	O
enamel	O
surface	O
exclusively	O
by	O
Er	B-I
:	I-I
YAG	I-I
laser	I-I
resulted	O
in	O
the	O
highest	O
degree	B-O
of	I-O
leakage	I-O
.	I-O


Dexmedetomidine	B-I
pretreatment	O
alleviates	O
propofol	B-P
injection	I-P
pain	I-P
.	I-P


OBJECTIVE	O
The	O
incidence	O
of	O
propofol	B-I
injection	O
pain	O
during	O
induction	O
of	O
general	O
anesthesia	O
varies	O
from	O
28	O
%	O
to	O
90	O
%	O
.	O


Experimental	O
treatments	O
were	O
intravenously	O
administered	O
over	O
10	O
min	O
(	O
total	O
volume	O
10	O
mL	O
)	O
prior	O
to	O
intravenous	O
propofol	B-I
injection	O
,	O
as	O
follows	O
:	O
group	O
I	O
,	O
the	O
control	O
group	O
,	O
was	O
given	O
isotonic	B-I
saline	I-I
.	I-I


The	B-O
median	I-O
pain	I-O
score	I-O
and	I-O
number	I-O
of	I-O
patients	I-O
with	I-O
pain	I-O
scores	I-O
>	O
2	O
in	O
group	O
VII	O
were	O
both	O
significantly	O
less	O
than	O
in	O
the	O
control	O
(	O
group	O
I	O
;	O
p	O
=	O
0.000	O
,	O
both	O
)	O
.	O


Patients	B-P
with	I-P
persistent	I-P
AF	I-P
or	I-P
AF	I-P
induced	I-P
during	I-P
a	I-P
routine	I-P
electrophysiology	I-P
study	I-P
(	I-P
EPS	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
either	O
the	O
low-tilt	B-I
waveform	I-I
or	O
a	O
conventional	B-I
waveform	I-I
.	I-I


Plasmakinetic	B-I
prostate	I-I
resection	I-I
in	O
the	O
treatment	O
of	O
benign	O
prostate	O
hyperplasia	O
:	O
results	O
of	O
1-year	O
follow	O
up	O
.	O


The	O
decrease	O
in	O
serum	B-O
Na	I-O
level	I-O
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
TURP	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Differential	O
response	O
to	O
resistance	B-I
training	I-I
in	O
CHF	O
according	O
to	O
ACE	O
genotype	O
.	O


We	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
ACE	O
genotype	O
on	O
the	O
response	O
to	O
moderate	O
intensity	O
circuit	O
resistance	B-I
training	I-I
in	O
chronic	B-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
patients	I-P
.	I-P


METHODS	O
The	O
relationship	O
between	O
ACE	O
genotype	O
and	O
the	O
response	O
to	O
11weeks	B-I
of	I-I
resistance	I-I
exercise	I-I
training	I-I
was	O
determined	O
in	O
37	B-P
CHF	I-P
patients	I-P
(	I-P
New	I-P
York	I-P
Heart	I-P
Association	I-P
Functional	I-P
Class=2.3±0.5	I-P
;	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
28±7	I-P
%	I-P
;	I-P
age	I-P
64±12years	I-P
;	I-P
32:5	I-P
male	I-P
:	I-P
female	I-P
)	I-P
who	I-P
were	I-P
randomised	I-P
to	O
either	B-I
resistance	I-I
exercise	I-I
(	O
n=19	O
)	O
or	B-I
inactive	I-I
control	I-I
group	I-I
(	O
n=18	O
)	O
.	O


Outcome	O
measures	O
included	B-O
V˙O	I-O
(	I-O
2peak	I-O
)	I-O
,	I-O
peak	I-O
power	I-O
output	I-O
and	I-O
muscle	I-O
strength	I-O
and	I-O
endurance	I-O
.	O


RESULTS	O
At	O
baseline	O
,	O
patients	O
who	O
were	O
homozygous	O
for	O
the	O
I	O
allele	O
had	O
higher	B-O
V˙O	I-O
(	I-O
2peak	I-O
)	I-O
(	I-O
p=0.02	I-O
)	I-O
and	I-O
peak	I-O
power	I-O
(	O
p=0.003	O
)	O
compared	O
to	O
patients	O
who	O
were	O
homozygous	O
for	O
the	O
D	O
allele	O
.	O


No	O
significant	O
genotype-dependent	O
changes	O
were	O
observed	B-O
in	I-O
V˙O	I-O
(	I-O
2peak	I-O
)	I-O
,	I-O
muscle	I-O
strength	I-O
,	I-O
muscle	I-O
endurance	I-O
or	I-O
lactate	I-O
threshold	I-O
.	O


Many	O
athletes	B-P
arrive	O
at	O
training	O
sessions	O
and	O
competitions	O
in	O
a	O
mildly	B-P
hypohydrated	I-P
(	I-P
HYPO	I-P
)	I-P
state	I-P
and	O
are	O
instructed	O
to	O
drink	O
fluids	O
before	O
exercise	O
to	O
reach	O
a	O
euhydrated	O
(	O
HYD	O
)	O
state	O
.	O


Ten	B-P
recreational	I-P
athletes	I-P
(	I-P
6	I-P
women	I-P
,	I-P
4	I-P
men	I-P
;	I-P
71.9	I-P
±	I-P
4.6	I-P
kg	I-P
,	I-P
25.2	I-P
±	I-P
0.9	I-P
years	I-P
)	I-P
participated	I-P
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	O
day-to-day	O
variability	O
of	O
morning	O
urine	O
specific	O
gravity	O
(	O
USG	O
)	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
consuming	B-I
600	I-I
ml	I-I
of	I-I
water	I-I
on	O
the	O
hydration	O
status	O
of	O
HYD	O
and	O
HYPO	O
(	O
USG	O
>	O
1.020	O
)	O
subjects	O
,	O
and	O
(	O
c	O
)	O
the	O
effects	O
of	O
consuming	B-I
water	I-I
(	I-I
W	I-I
)	I-I
,	I-I
salt-water	I-I
(	O
SW	O
,	O
40	O
mM	O
Na	O
)	O
,	O
a	B-I
carbohydrate-electrolyte	I-I
solution	I-I
with	I-I
3	I-I
%	I-I
or	I-I
light	I-I
carbohydrate	I-I
(	O
CES-L	O
,	O
20	O
mM	O
Na	O
)	O
or	O
a	B-I
CES	I-I
with	I-I
6	I-I
%	I-I
carbohydrate	I-I
(	O
CES	O
,	O
20	O
mM	O
Na	O
)	O
on	O
the	O
hydration	O
status	O
of	O
HYPO	O
subjects	O
.	O


The	O
day-to-day	O
variability	O
in	O
morning	O
USG	O
(	O
coefficient	O
of	O
variation	O
=	O
0.2	O
±	O
0.1	O
%	O
)	O
was	O
low	O
and	O
the	O
responses	O
to	O
600	O
ml	O
of	O
W	O
ingestion	O
were	O
repeatable	B-O
.	I-O


In	O
the	O
CES	O
study	O
,	O
HYPO	O
subjects	O
reached	O
HYD	O
status	O
at	O
45	O
minutes	O
in	O
all	O
conditions	O
(	O
W	O
1.013	O
±	O
0.003	O
,	O
SW	O
1.013	O
±	O
0.003	O
,	O
CES-L	O
1.011	O
±	O
0.003	O
,	O
CES	O
1.017	O
±	O
0.004	O
)	O
because	O
salt	O
or	O
CES	O
ingestion	O
did	O
not	B-O
affect	I-O
fluid	I-O
retention	I-O
(	O
W	O
68	O
%	O
,	O
SW	O
72	O
%	O
,	O
CES-L	O
68	O
%	O
,	O
CES	O
76	O
%	O
)	O
.	O


Following	O
baseline	O
(	O
6	O
weeks	O
)	O
,	O
patients	O
entered	O
a	O
19-week	O
double-blind	O
phase	B-I
:	I-I
6-week	I-I
titration	I-I
(	I-I
2	I-I
mg/week	I-I
increments	I-I
to	I-I
target	I-I
dose	I-I
)	I-I
followed	I-I
by	I-I
a	I-I
13-week	I-I
maintenance	I-I
period	I-I
.	O


Using	O
this	O
intent-to-treat	O
population	O
over	O
the	O
double-blind	O
phase	O
,	O
the	B-O
median	I-O
percent	I-O
change	I-O
in	I-O
seizure	I-O
frequency	I-O
was	O
-21.0	O
%	O
,	O
-26.3	O
%	O
,	O
and	O
-34.5	O
%	O
for	B-I
placebo	I-I
and	I-I
perampanel	I-I
8	O
and	O
12	O
mg	O
,	O
respectively	O
(	O
p	O
=	O
0.0261	O
and	O
p	O
=	O
0.0158	O
for	O
8	O
and	O
12	O
mg	O
vs	O
placebo	O
,	O
respectively	O
)	O
.	O


Fifty	O
percent	O
responder	O
rates	O
during	O
the	O
maintenance	O
period	O
were	O
26.4	O
%	O
,	O
37.6	O
%	O
,	O
and	O
36.1	O
%	O
,	O
respectively	O
,	O
for	B-I
placebo	I-I
,	I-I
perampanel	I-I
8	O
mg	O
,	O
and	B-I
perampanel	I-I
12	O
mg	O
;	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
for	O
8	O
mg	O
(	O
p	O
=	O
0.0760	O
)	O
or	O
12	O
mg	O
(	O
p	O
=	O
0.0914	B-P
)	I-P
.	I-P


